<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id><journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id><journal-id journal-id-type="publisher-id">ci</journal-id><journal-id journal-id-type="coden">jcisd8</journal-id><journal-title-group><journal-title>Journal of Chemical Information and Modeling</journal-title></journal-title-group><issn pub-type="ppub">1549-9596</issn><issn pub-type="epub">1549-960X</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1021/acs.jcim.0c00501</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Decoding SARS-CoV-2 Transmission and Evolution and Ramifications
for COVID-19 Diagnosis, Vaccine, and Medicine</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Wang</surname><given-names>Rui</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Hozumi</surname><given-names>Yuta</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath3"><name><surname>Yin</surname><given-names>Changchuan</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath4"><name><surname>Wei</surname><given-names>Guo-Wei</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department of Mathematics,
<institution>Michigan State University</institution>, East
Lansing, Michigan 48824, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department of Mathematics, Statistics,
and Computer Science, <institution>University of Illinois at
Chicago</institution>, Chicago, Illinois 60607, <country>United
States</country></aff><aff id="aff3"><label>&#x000a7;</label>Department of Biochemistry and Molecular
Biology, <institution>Michigan State University</institution>, East
Lansing, Michigan 48824, <country>United States</country></aff><aff id="aff4"><label>&#x02225;</label>Department of Electrical and Computer
Engineering, <institution>Michigan State University</institution>,
East Lansing, Michigan 48824, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>cyin1@uic.edu</email>
(C.Y.).</corresp><corresp id="cor2"><label>*</label>E-mail: <email>wei@math.msu.edu</email>
(G.-W.W.).</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>06</month><year>2020</year></pub-date><elocation-id>acs.jcim.0c00501</elocation-id><history><date date-type="received"><day>09</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 American Chemical Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for
unrestricted RESEARCH re-use and analyses in any form or by any
means with acknowledgement of the original source. These
permissions are granted for the duration of the World Health
Organization (WHO) declaration of COVID-19 as a global
pandemic.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0014" id="ab-tgr1"/></p><p>Tremendous effort has been given to the development of diagnostic
tests, preventive vaccines, and therapeutic medicines for
coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Much of this
development has been based on the reference genome collected on
January 5, 2020. Based on the genotyping of 15&#x0202f;140 genome
samples collected up to June 1, 2020, we report that SARS-CoV-2
has undergone 8309 single mutations which can be clustered into
six subtypes. We introduce mutation ratio and mutation
<italic>h</italic>-index to characterize the protein
conservativeness and unveil that SARS-CoV-2 envelope protein,
main protease, and endoribonuclease protein are relatively
conservative, while SARS-CoV-2 nucleocapsid protein, spike
protein, and papain-like protease are relatively
nonconservative. In particular, we have identified mutations on
40% of nucleotides in the nucleocapsid gene in the population
level, signaling potential impacts on the ongoing development of
COVID-19 diagnosis, vaccines, and antibody and small-molecular
drugs.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ci0c00501</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ci0c00501</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed crucial
threats to public health and the world economy since it was detected in
Wuhan, China, in December 2019.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> As of June 1, 2020,
6&#x0202f;057&#x0202f;853 cases of COVID-19 have been reported in more than
200 countries and territories, resulting in more than 371&#x0202f;166
deaths.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> However, there have been no signs of
slowing down nor relief at this monument partially due to the fact there are
no specific anti-SARS-CoV-2 drugs and effective vaccines.</p><p>SARS-CoV-2 is a positive-strand RNA virus that belongs to the beta coronavirus
genus. The genomic information underpins the development of antiviral
medical interventions, prophylactic vaccines, and viral diagnostic tests.
The first SARS-CoV-2 genome was reported on January 5, 2020.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> It has a genome size of 29.99 kb, which encodes for
multiple nonstructural and structural proteins. The leader sequence and
ORF1ab encode nonstructural proteins for RNA replication and transcription.
Among various nonstructural proteins, viral papain-like (PL) proteinase,
main protease (or 3CL protease), RNA polymerase, and endoribonuclease are
the common targets in antiviral drug discovery. Yet, it typically takes more
than ten years to put an average drug to the market. The downstream regions
of the genome encode structural proteins, including spike (S) protein,
envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein.
Notably, S-protein uses one of its two subunits to bind directly to the host
receptor angiotensin-converting enzyme 2 (ACE2), enabling virus entry into
host cells.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The N protein, one of the most abundant
viral proteins, can bind to the RNA genome and is involved in replication,
assembly, and host cellular response during viral infection.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> As a virulence factor, the E protein is a small integral
membrane protein that regulates cell stress response and apoptosis and
promotes inflammation.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> The structural protein,
especially, the S protein, is the candidate antigen for vaccine and antibody
drug development. Developing safe and effective vaccines is urgently needed
to prevent the spread of SARS-CoV-2. However, it typically takes over one
year to design and test a new vaccine. Furthermore, the replication in RNA
viruses, such as Influenza A, is subject to errors,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup>
except nidoviruses. Coronaviruses, a kind of nidoviruses, have the ability
to proofread their genomes during their genetic replication and
recombination.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Therefore, SARS-CoV-2 might not
mutate as fast as Influenza A viruses do, but still has heterogeneous and
dynamic populations. The SARS-CoV-2 genome undergoes rapid mutations that
are partially stimulated as a response to the challenging immunological
environments arising from its transmission to the COVID-19 patients of
different races, ages, and medical conditions.</p><p>The vaccine developed at one time may not be effective for mitigating the
infection by new mutated virus isolates. An alarming fact is that many of
these mutations may devastate the ongoing effort in the development of
effective medicines, preventive vaccines, and diagnostic tests. Accurate
identification of the antigens and their mutations represents the most
important roadblock in developing effective vaccines against COVID-19. For
example, different vaccines are needed for various geographic locations due
to predominant mutations in the corresponding regions. In COVID-19
diagnosis, the diagnostic kits are designed using two major methods:
serological tests and molecular tests. Serological tests are to detect
specific neutralizing antibodies from COVID-19 infections. Molecular
diagnoses look for specific COVID-19 pathogenic genes, which usually rely on
the polymerase chain reaction (PCR). Because of the fast mutations of the
SARS-CoV-2 genome, genotyping analysis of SARS-CoV-2 may optimize the PCR
primer design to detect SARS-CoV safely and to reduce the risk of
false-negatives caused by genome sequence variations. In addition, the
genotyping analysis may also reveal those highly conserved regions with very
few mutations, which can be selected as a target sequence for clinical
diagnosis and effective drug therapy.</p><p>The evolution pattern through the highly frequent mutations of SARS-CoV-2 can
be observable on short time scales. In the early infection period (i.e.,
February 2020), the SARS-CoV-2 variants were clustered as S and L
types.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Recent genotyping analysis reveals a large
number of mutations in various essential genes encoding the S protein, the N
protein, and the RNA polymerase in the SARS-CoV-2 population.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> Monitoring the evolutionary patterns and spread dynamics
of SARS-CoV-2 is of great importance for COVID-19 control and
prevention.</p><p>Mutations occur in many different ways. Some mutations occur randomly. Other
mutations are enforced by the host immune system surveillance, which induces
viral responses. The most preserved mutations and viral evolution can be
regarded as the result of the dynamic equilibrium between the random
perturbation, host cell defense, and viral fitness. Therefore, the faster
and wider the SARS-CoV-2 spread, the more frequent and diverse the mutations
will be. The tracking and analysis of COVID-19 dynamics, transmission, and
spread are of paramount importance for winning the ongoing battle against
COVID-19. Genetic identification and characterization of the geographic
distribution, intercontinental evolution, and global trends of SARS-CoV-2
are the most effective approaches for studying COVID-19 genomic epidemiology
and offer the molecular foundation for region-specific SARS-CoV-2 vaccine
design, drug discovery, and diagnostic development.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> For
example, different vaccines for the shell can be designed according to
predominant mutations.</p><p>This work provides the most comprehensive genotyping to reveal the transmission
trajectory and spread dynamics of COVID-19 to date. Based on genotyping
15&#x0202f;140 SARS-CoV-2 genomes from the world as of June 1, 2020, we trace
the COVID-19 transmission pathways and analyze the distribution of the
subtypes of SARS-CoV-2 across the world. We use <italic>K</italic>-means
methods to cluster SARS-CoV-2 mutations, which provides updated molecular
information for the region-specific design of vaccines, drugs, and
diagnoses. Our clustering results show that, globally, there are at least
six distinct subtypes of SARS-CoV-2 genomes. While, in the U.S., there are
four significant SARS-CoV-2 genotypes. We introduce mutation
<italic>h</italic>-index and mutation ratio to characterize
conservative and nonconservative proteins and genes. We unveil the
unexpected nonconservative genes and proteins, rendering a warning for the
current development of diagnostic tests, preventive vaccines, and
therapeutic medicines.</p></sec><sec id="sec2"><label>2</label><title>Results and Discussion</title><sec id="sec2.1"><label>2.1</label><title>COVID-19 Evolution and Clustering</title><p>Tracking the SARS-CoV-2 transmission pathways and analyzing the spread
dynamics are critical to the study of genomic epidemiology.
Temporospatially clustering the genotypes of SARS-CoV-2 in the
transmission provides insights into diagnostic testing and vaccine
development in disease control. In this work, we retrieve and genotype
15&#x0202f;140 SARS-CoV-2 isolates from the world as of June 1, 2020.
There are 8309 single mutations in 15&#x0202f;140 SARS-CoV-2 isolates.
Based on these mutations, we classify and track the geographical
distributions of 15&#x0202f;140 genotype isolates by
<italic>K</italic>-means clustering. The SARS-CoV-2 genotypes,
represented as single nucleotide polymorphism (SNP) variants, are
clustered as six groups in the world, including the U.S.. In
particular, the genotypes in the U.S. are further clustered into four
groups. <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref> lists the
co-mutations with the highest number of descendants in different
clusters in the world. Optimal clustering groups are established using
the Elbow method in the <italic>K</italic>-means clustering algorithm
(<xref rid="notes1" ref-type="notes">Supporting Information</xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Co-mutations with the Highest Number of Descendants in
Six Distinct Clusters in the World</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">cluster</th><th style="border:none;" align="center">mutation sites</th><th style="border:none;" align="center" char=".">number of
descendants</th></tr></thead><tbody><tr><td style="border:none;" align="left">I</td><td style="border:none;" align="left">[3037C&#x0003e;T, 14408C&#x0003e;T]</td><td style="border:none;" align="char" char=".">10875</td></tr><tr><td style="border:none;" align="left">II</td><td style="border:none;" align="left">[3037C&#x0003e;T, 14408C&#x0003e;T,
23403A&#x0003e;G]</td><td style="border:none;" align="char" char=".">10830</td></tr><tr><td style="border:none;" align="left">III</td><td style="border:none;" align="left">[14408C&#x0003e;T]</td><td style="border:none;" align="char" char=".">10923</td></tr><tr><td style="border:none;" align="left">IV</td><td style="border:none;" align="left">[3037C&#x0003e;T, 14408C&#x0003e;T, 23403A&#x0003e;G,
28881G&#x0003e;A, 28882G&#x0003e;A, 28883G&#x0003e;C]</td><td style="border:none;" align="char" char=".">3043</td></tr><tr><td style="border:none;" align="left">V</td><td style="border:none;" align="left">[3037C&#x0003e;T, 14408C&#x0003e;T, 23403A&#x0003e;G,
25563G&#x0003e;T]</td><td style="border:none;" align="char" char=".">4632</td></tr><tr><td style="border:none;" align="left">VI</td><td style="border:none;" align="left">[8782C&#x0003e;T, 28144T&#x0003e;C]</td><td style="border:none;" align="char" char=".">1722</td></tr></tbody></table></table-wrap><p>The detailed distribution of the SNP variants from the world for each
cluster is provided in the <xref rid="notes1" ref-type="notes">Supporting
Information</xref>. The SNP variant clusters from 76 countries
that have a high number of the COVID-19 cases are listed in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>. The listed countries
are the United States (US), Canada (CA), Australia (AU), United
Kingdom (UK), Germany (DE), France (FR), Italy (IT), Russia (RU),
China (CN), Japan (JP), Korean (KR), India (IN), Spain (ES), Saudi
Arabia (SA), and Turkey (TR). The pie chart plot on the world map is
described in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> which
was created by Highcharts (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.highcharts.com/maps/demo">https://www.highcharts.com/maps/demo</uri>). The light blue,
dark blue, green, red, purple, and yellow represent the Cluster I, II,
III, IV, V, and VI, respectively. The color of the dominated cluster
decides the base color of each country. The geographic distribution of
the SNP variant clusters reflects the approximate transmission
pathways and spread dynamics across the world. Several findings can be
made from <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>:<list id="list1" list-type="simple"><list-item><label>1.</label><p>Subtypes from
clusters III and IV are causing the epidemic in the
Asian countries, including those in CN, JP, and
KR.</p></list-item><list-item><label>2.</label><p>The
subtypes of SARS-CoV-2 in cluster VI are not
spreading in the European countries (UK, DE, FR, IT,
RU).</p></list-item><list-item><label>3.</label><p>All
of the subtypes of SARS-CoV-2 in six different
clusters can be found in CN, US, CA, AU, and ES.
Among them, China initially had samples only in
clusters III and VI, and its sample distributions
reached to other clusters after the middle of March
2020.</p></list-item><list-item><label>4.</label><p>The
dominant subtypes of SARS-CoV-2 in the COVID-19
pandemic of the United States belong to all of the
six clusters.</p></list-item></list></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Pie chart plot of six distinct clusters in the world. The
light blue, dark blue, green, red, purple, and yellow
represent clusters I, II, III, IV, V, and VI,
respectively. The base color of each country is decided by
the color of the dominant cluster.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0001" id="gr1" position="float"/></fig><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Cluster Distributions of Samples from 15
Countries</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">country</th><th style="border:none;" align="center" char=".">cluster&#x000a0;I</th><th style="border:none;" align="center" char=".">cluster&#x000a0;II</th><th style="border:none;" align="center" char=".">cluster&#x000a0;III</th><th style="border:none;" align="center" char=".">cluster&#x000a0;IV</th><th style="border:none;" align="center" char=".">cluster&#x000a0;V</th><th style="border:none;" align="center" char=".">cluster&#x000a0;VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">US</td><td style="border:none;" align="char" char=".">844</td><td style="border:none;" align="char" char=".">311</td><td style="border:none;" align="char" char=".">488</td><td style="border:none;" align="char" char=".">156</td><td style="border:none;" align="char" char=".">1813</td><td style="border:none;" align="char" char=".">975</td></tr><tr><td style="border:none;" align="left">CA</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="char" char=".">29</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">19</td><td style="border:none;" align="char" char=".">41</td></tr><tr><td style="border:none;" align="left">AU</td><td style="border:none;" align="char" char=".">163</td><td style="border:none;" align="char" char=".">149</td><td style="border:none;" align="char" char=".">410</td><td style="border:none;" align="char" char=".">135</td><td style="border:none;" align="char" char=".">146</td><td style="border:none;" align="char" char=".">77</td></tr><tr><td style="border:none;" align="left">UK</td><td style="border:none;" align="char" char=".">539</td><td style="border:none;" align="char" char=".">875</td><td style="border:none;" align="char" char=".">908</td><td style="border:none;" align="char" char=".">1532</td><td style="border:none;" align="char" char=".">119</td><td style="border:none;" align="char" char=".">3</td></tr><tr><td style="border:none;" align="left">DE</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">21</td><td style="border:none;" align="char" char=".">38</td><td style="border:none;" align="char" char=".">42</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">FR</td><td style="border:none;" align="char" char=".">41</td><td style="border:none;" align="char" char=".">85</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="char" char=".">82</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">IT</td><td style="border:none;" align="char" char=".">26</td><td style="border:none;" align="char" char=".">24</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">RU</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">27</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">109</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">CN</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">215</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">25</td></tr><tr><td style="border:none;" align="left">JP</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">68</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">KR</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">IN</td><td style="border:none;" align="char" char=".">93</td><td style="border:none;" align="char" char=".">69</td><td style="border:none;" align="char" char=".">141</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">ES</td><td style="border:none;" align="char" char=".">27</td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">74</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left">SA</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">31</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">TR</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">24</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap><p>The cluster analysis reveals that the Asian countries have three dominant
subtype clusters, cluster III [14408C&#x0003e;T], cluster IV [3037C&#x0003e;T,
14408C&#x0003e;T, 23403A&#x0003e;G, 28881G&#x0003e;A, 28882G&#x0003e;A, 28883G&#x0003e;C], and
cluster VI [8782C&#x0003e;T, 28144T&#x0003e;C]. Cluster III was detected in the
early period of COVID-19 infection in China and other Asian countries.
The subtype of SNP mutation in S protein, 23403A&#x0003e;G, is prevalent in
the clusters II, IV, and V of European countries. This subtype of S
protein mutation may have resulted in the wide spread of SARS-CoV-2 in
European countries.</p><p>Furthermore, we analyze the statistics of SNP variants located in the
United States. In <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>, we
list the number of cases in four different clusters with respect to
the west coast states (Washington (WA), California (CA), Alaska (AK),
and Oregon (OR)), the east coast cities and states (New York (NY),
Washington, D.C. (DC), Pennsylvania (PA), Florida (FL), Massachusetts
(MA), Maryland (MD), Virginia (VA)), Wisconsin (WI), Minnesota (MN),
Michigan (MI), Georgia (GA), Utah (UT), Connecticut (CT), Arizona
(AZ), Idaho (ID), and Illinois (IL). <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref> lists the co-mutations with the
highest number of descendants in different clusters in the United
States. Notably, several findings on the genotypes of clusters in the
US are as follows:<list id="list2" list-type="simple"><list-item><label>1.</label><p>The subtypes of
SARS-CoV-2 in all of the clusters are spreading out
among the west coast states. Especially, the state
of Washington is dominated by cluster
B.</p></list-item><list-item><label>2.</label><p>East
coast states are dominated by subtypes from clusters
A and C, especially in New
York.</p></list-item><list-item><label>3.</label><p>The
subtypes of SARS-CoV-2 in cluster A are spread
throughout the United
States.</p></list-item></list></p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Cluster Distributions of Samples from 20 States and
Cities in the United States</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">state</th><th style="border:none;" align="center" char=".">cluster A</th><th style="border:none;" align="center" char=".">cluster B</th><th style="border:none;" align="center" char=".">cluster C</th><th style="border:none;" align="center" char=".">cluster D</th></tr></thead><tbody><tr><td style="border:none;" align="left">WA</td><td style="border:none;" align="char" char=".">304</td><td style="border:none;" align="char" char=".">805</td><td style="border:none;" align="char" char=".">40</td><td style="border:none;" align="char" char=".">355</td></tr><tr><td style="border:none;" align="left">CA</td><td style="border:none;" align="char" char=".">88</td><td style="border:none;" align="char" char=".">53</td><td style="border:none;" align="char" char=".">112</td><td style="border:none;" align="char" char=".">82</td></tr><tr><td style="border:none;" align="left">AK</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">11</td></tr><tr><td style="border:none;" align="left">OR</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">NY</td><td style="border:none;" align="char" char=".">324</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">66</td><td style="border:none;" align="char" char=".">807</td></tr><tr><td style="border:none;" align="left">DC</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">7</td></tr><tr><td style="border:none;" align="left">PA</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">6</td></tr><tr><td style="border:none;" align="left">FL</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">4</td></tr><tr><td style="border:none;" align="left">MA</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">9</td></tr><tr><td style="border:none;" align="left">MD</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">5</td></tr><tr><td style="border:none;" align="left">VA</td><td style="border:none;" align="char" char=".">67</td><td style="border:none;" align="char" char=".">11</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">65</td></tr><tr><td style="border:none;" align="left">WI</td><td style="border:none;" align="char" char=".">150</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">151</td><td style="border:none;" align="char" char=".">57</td></tr><tr><td style="border:none;" align="left">MN</td><td style="border:none;" align="char" char=".">29</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">19</td><td style="border:none;" align="char" char=".">57</td></tr><tr><td style="border:none;" align="left">MI</td><td style="border:none;" align="char" char=".">11</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">72</td></tr><tr><td style="border:none;" align="left">GA</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">11</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left">UT</td><td style="border:none;" align="char" char=".">13</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">23</td></tr><tr><td style="border:none;" align="left">CT</td><td style="border:none;" align="char" char=".">39</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">14</td></tr><tr><td style="border:none;" align="left">AZ</td><td style="border:none;" align="char" char=".">31</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">35</td></tr><tr><td style="border:none;" align="left">ID</td><td style="border:none;" align="char" char=".">31</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">8</td></tr><tr><td style="border:none;" align="left">IL</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">19</td><td style="border:none;" align="char" char=".">20</td></tr><tr><td style="border:none;" align="left">others</td><td style="border:none;" align="char" char=".">146</td><td style="border:none;" align="char" char=".">13</td><td style="border:none;" align="char" char=".">39</td><td style="border:none;" align="char" char=".">173</td></tr><tr><td style="border:none;" align="left">total</td><td style="border:none;" align="char" char=".">1308</td><td style="border:none;" align="char" char=".">970</td><td style="border:none;" align="char" char=".">497</td><td style="border:none;" align="char" char=".">1812</td></tr></tbody></table></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Mutation Sites with Highest Frequency in Each Cluster in
the United States</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">mutation sites</th><th style="border:none;" align="center" char=".">number of
descendants</th></tr></thead><tbody><tr><td style="border:none;" align="left">cluster A</td><td style="border:none;" align="left">[3037C&#x0003e;T, 14408C&#x0003e;T]</td><td style="border:none;" align="char" char=".">10875</td></tr><tr><td style="border:none;" align="left">cluster B</td><td style="border:none;" align="left">[8782C &#x0003e; T, 18060C&#x0003e;T,
28144T&#x0003e;C]</td><td style="border:none;" align="char" char=".">1127</td></tr><tr><td style="border:none;" align="left">cluster C</td><td style="border:none;" align="left">[11083G&#x0003e;T]</td><td style="border:none;" align="char" char=".">1646</td></tr><tr><td style="border:none;" align="left">cluster D</td><td style="border:none;" align="left">[241C&#x0003e;T, 3037C&#x0003e;T, 14408C&#x0003e;T,
23403A&#x0003e;G, 25563G&#x0003e;T]</td><td style="border:none;" align="char" char=".">4494</td></tr></tbody></table></table-wrap><p><xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> is the pie chart plot
of the four distinct clusters in the US, which was also created by
Highcharts. The colors, blue, red, yellow, and green represent
clusters A, B, C, and D, respectively. The base color of each state
corresponds to its dominant cluster. We note that cluster D in the
U.S. is derived from cluster V in the world, with an additional
mutation at the leader sequence 241. The high spread in New York is
consistent with the high transmission of SARS-CoV-2 in European
countries, where the subtype in cluster V is predominant.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Pie chart plot of four distinct clusters in the US. The blue,
red, yellow, and green colors represent clusters A, B, C,
and D. The base color of each state corresponds to its
dominant cluster.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0002" id="gr2" position="float"/></fig></sec><sec id="sec2.2"><label>2.2</label><title>Ramifications for COVID-19 Diagnosis, Vaccine, and Medicine</title><sec id="sec2.2.1"><label>2.2.1</label><title>Protein-Specific Mutation Analysis</title><p><xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref> and <xref rid="fig4" ref-type="fig">4</xref> depict the distribution and frequencies of
SNP mutations of SARS-CoV-2 isolates from 15&#x0202f;140 genome
samples in the world with respect to the reference genome of
January 5, 2020. The statistics of single mutations on various
SARS-CoV-2 proteins that occurred in the recorded genomes
between January 5, 2020, and June 1, 2020, are listed in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>. The spike
protein has the highest number of mutations on gene of 1004,
while the envelope protein has the lowest number of mutations of
52. Since the sizes of proteins vary dramatically from 1273 for
the spike protein to 75 for the envelope protein, it is useful
to consider the mutation ratio, i.e., the number of mutations
per residue. In this category, the RNA-dependent RNA polymerase
has the lowest score of 0.217, whereas the nucleocapsid protein
has the highest score of 0.400, i.e, 503 mutations on its 1257
nucleotides (419 residues). Note that main protease has the
second-lowest mutation ratio of 0.221, indicating its
conservative nature. Another relatively conservative protein
judged by the mutations ratio in terms of gene is the envelope
protein, the MR<sub>Gene</sub> = 0.231.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Distribution of SNP mutations of SARS-CoV-2 isolates
from 15&#x0202f;140 genome samples in the world with
respect to the reference genome of January 5, 2020
(GenBank access number: NC_045512.2).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0003" id="gr3" position="float"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Frequencies of the single SNP mutations of SARS-CoV-2
on the genome samples in the world with respect to
the reference genome of January 5, 2020 (GenBank
access number: NC_045512.2).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0004" id="gr4" position="float"/></fig><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title>Protein-Specific and Gene-Specific Statistics of
SARS-CoV-2 Single Mutations<xref rid="tbl5-fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">protein</th><th style="border:none;" align="center" char=".">gene length</th><th style="border:none;" align="center" char=".">protein length</th><th style="border:none;" align="center" char=".">NM<sub>Gene</sub></th><th style="border:none;" align="center" char=".">NM<sub>Pro</sub></th><th style="border:none;" align="center" char=".">MR<sub>Gene</sub></th><th style="border:none;" align="center" char=".">MR<sub>Pro</sub></th><th style="border:none;" align="center" char=".">mutation
<italic>h</italic>-index</th></tr></thead><tbody><tr><td style="border:none;" align="left">spike protein</td><td style="border:none;" align="char" char=".">3819</td><td style="border:none;" align="char" char=".">1273</td><td style="border:none;" align="char" char=".">1004</td><td style="border:none;" align="char" char=".">391</td><td style="border:none;" align="char" char=".">0.263</td><td style="border:none;" align="char" char=".">0.307</td><td style="border:none;" align="char" char=".">26</td></tr><tr><td style="border:none;" align="left">main protease</td><td style="border:none;" align="char" char=".">918</td><td style="border:none;" align="char" char=".">306</td><td style="border:none;" align="char" char=".">203</td><td style="border:none;" align="char" char=".">78</td><td style="border:none;" align="char" char=".">0.221</td><td style="border:none;" align="char" char=".">0.255</td><td style="border:none;" align="char" char=".">16</td></tr><tr><td style="border:none;" align="left">papain-like protease</td><td style="border:none;" align="char" char=".">945</td><td style="border:none;" align="char" char=".">315</td><td style="border:none;" align="char" char=".">187</td><td style="border:none;" align="char" char=".">105</td><td style="border:none;" align="char" char=".">0.255</td><td style="border:none;" align="char" char=".">0.333</td><td style="border:none;" align="char" char=".">10</td></tr><tr><td style="border:none;" align="left">RNA polymerase</td><td style="border:none;" align="char" char=".">2796</td><td style="border:none;" align="char" char=".">932</td><td style="border:none;" align="char" char=".">607</td><td style="border:none;" align="char" char=".">228</td><td style="border:none;" align="char" char=".">0.217</td><td style="border:none;" align="char" char=".">0.245</td><td style="border:none;" align="char" char=".">21</td></tr><tr><td style="border:none;" align="left">endoribo-nuclease</td><td style="border:none;" align="char" char=".">1038</td><td style="border:none;" align="char" char=".">346</td><td style="border:none;" align="char" char=".">256</td><td style="border:none;" align="char" char=".">110</td><td style="border:none;" align="char" char=".">0.247</td><td style="border:none;" align="char" char=".">0.318</td><td style="border:none;" align="char" char=".">12</td></tr><tr><td style="border:none;" align="left">envelope (E) protein</td><td style="border:none;" align="char" char=".">225</td><td style="border:none;" align="char" char=".">75</td><td style="border:none;" align="char" char=".">52</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">0.231</td><td style="border:none;" align="char" char=".">0.307</td><td style="border:none;" align="char" char=".">9</td></tr><tr><td style="border:none;" align="left">membrane protein</td><td style="border:none;" align="char" char=".">666</td><td style="border:none;" align="char" char=".">222</td><td style="border:none;" align="char" char=".">165</td><td style="border:none;" align="char" char=".">60</td><td style="border:none;" align="char" char=".">0.248</td><td style="border:none;" align="char" char=".">0.270</td><td style="border:none;" align="char" char=".">14</td></tr><tr><td style="border:none;" align="left">nucleocapsid (N) protein</td><td style="border:none;" align="char" char=".">1257</td><td style="border:none;" align="char" char=".">419</td><td style="border:none;" align="char" char=".">503</td><td style="border:none;" align="char" char=".">205</td><td style="border:none;" align="char" char=".">0.400</td><td style="border:none;" align="char" char=".">0.489</td><td style="border:none;" align="char" char=".">33</td></tr></tbody></table><table-wrap-foot><fn id="tbl5-fn1"><label>a</label><p>NM<sub>Gene</sub> and NM<sub>Pro</sub> are the
number of mutations in terms of gene and protein,
respectively. MR<sub>Gene</sub> is the mutation
ratio of gene, and MR<sub>Pro</sub> is the ratio
of the non-degenerated mutations of a protein.
Mutation <italic>h</italic>-index focus on the
gene-specific <italic>h</italic>-index.</p></fn></table-wrap-foot></table-wrap><p>Counting the number of single mutations and mutation ratio does not
reflect the fact that some mutations occur numerous times over
genome samples while other mutations may happen only on a few
genome samples. To account for the frequency effect of
mutations, we introduce a mutation <italic>h</italic>-index to
measure both the number of mutations and the frequency of
mutations of a given protein or genetic section. It is defined
as the maximum value of <italic>h</italic> such that the given
protein genetic section has <italic>h</italic> single mutations
that have each occurred at least <italic>h</italic> times. It is
very interesting to note from <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref> that the mutation
<italic>h</italic>-index correlates very well with the
number of mutations on gene; the Pearson correlation coefficient
is 0.711. Specifically, N protein has both the highest
MR<sub>Gene</sub> of 0.400 and the highest
<italic>h</italic>-index of 33, suggesting that it is the
most nonconservative protein in SARS-CoV-2 genomes. In contrast,
the envelope protein has the third-lowest number of mutations
per residues of 0.231 and the lowest <italic>h</italic>-index of
9, indicating its relatively conservative nature. By combining
the number of mutations per residue and the mutation
<italic>h</italic>-index, we report that the most
conservative SARS-CoV-2 proteins is the envelope. It is found
that the most nonconservative SARS-CoV-2 proteins are (1) the
nucleocapsid protein, (2) the spike protein, and (3) the
papain-like protease.</p><p>The number of mutations in terms of gene (NM<sub>Gene</sub>) and
the number of mutations in terms of protein (NM<sub>Pro</sub>)
we reported are accumulated numbers that from all of the
15&#x0202f;140 genome isolates. If we focus on the single genome
isolate, the maximum number of mutations on the whole genome
sequence is 24.</p></sec><sec id="sec2.2.2"><label>2.2.2</label><title>Diagnosis</title><p>Real-time RT-PCR (rRT-PCR) is routinely used in the qualitative
detection of nucleic acid from SARS-CoV-2 for diagnostic testing
COVID-19.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> The primers used in the
rRT-PCR are critical for the precise diagnosis of COVID-19 and
the discovery of new strains. The primer sequences are specially
designed for amplifying the conserved regions across the
different existing strains for high specificity and sensitivity
and also are subject to genotype changes as the SARS-CoV-2
coronavirus evolves. In diagnostic testing COVID-19, many
rRT-PCR primers are designed to detect for three perceived
conservative SARS-CoV-2 regions: (1) RNA-dependent RNA
polymerase (RdRP) gene in ORF1ab region, (2) the E protein gene,
and (3) the N protein gene.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Our genotyping
statistics given in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref> indicate that the nucleocapsid protein is the
worst choice.</p><p>Among the four structural proteins of SARS-CoV-2, the spike surface
glycoprotein (S) of 1273 amino acid residues, nucleocapsid
protein (N) of 419 amino acid residues, membrane protein (M) of
222 amino acid residues, and envelope protein (E protein) of 75
amino acid residues, the S protein is the most divergent with
1004 unique mutations among the 15&#x0202f;140 SARS-CoV-2
genomes. The N protein has 503 unique mutations, and the
envelope (E) protein has 52 mutations. Considering the lengths
of the proteins, all the four structural proteins undergo many
mutations. The RdRP gene, which is often used in diagnostic
testing COVID-19, also has 607 mutations.</p><p>Therefore, all three regions in the routine rRT-PCR target, namely
RdRP, the N protein gene, and the E protein genes, have
significant mutations. Precise and robust diagnosis tools must
be re-established according to the conserved regions and
predominated mutations in the SARS-CoV-2 genomes detailed in the
<xref rid="notes1" ref-type="notes">Supporting Information</xref>.</p></sec><sec id="sec2.2.3"><label>2.2.3</label><title>Vaccine Development</title><p>Vaccines are mostly associated with the S protein. Compared to
SARS-CoV, SARS-CoV-2 has a unique furin cleavage site, where
four amino acid residues (PRRA) are inserted into the
S1&#x02013;S2 junction region 681&#x02013;684 of the S
protein.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> The furin cleavage site is
crucial for zoonotic transmission of SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> This study reveals crucial mutations near the
S1&#x02013;S2 junction region in the S protein, including
23403A&#x0003e;G-(D614G), 23422C&#x0003e;T-(V620V), 23575C&#x0003e;T-(C671C),
23586A&#x0003e;G-(Q675R), 23611G&#x0003e;A-(R683R), 23707C&#x0003e;T-(P715P),
23731C&#x0003e;T-(T723T), 23849T&#x0003e;C-(L763L), and
23929C&#x0003e;T-(Y789Y). Moreover, these mutations of the S protein
SARS-CoV-2 are located at the epitope region, corresponding to
the regions 469&#x02013;882 and 599&#x02013;620 in
SARS-CoV.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p><p>Additionally, many mutated amino acids are on the receptor-binding
domain (RBD) of the S protein, as shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>. Unfortunately, the S
protein is the second most nonconservative protein in the genome
based on the number of mutations per residue and mutation
<italic>h</italic>-index. In fact, about half of the
receptor-binding domain residues of the S proteins have had
mutations in the past few months as shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>. Because the surface
accessibility of epitope is also important for the interaction
of antibody and antigen, these mutations are critical for the
antigenicity of the S protein.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Illustration of SARS-CoV-2 spike protein mutations
using 6VXX as a template.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0005" id="gr5" position="float"/></fig><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Illustration of SARS-CoV-2 spike-protein receptor
binding domain (RBD) mutation using 6M0J
as a template. It is noted that nearly half of the
residues in RBD have undergone mutations in the few
months.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0006" id="gr6" position="float"/></fig><p>Convalescent COVID-19 patients show a neutralizing antibody
response after infection, which is directed mostly against the S
protein.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> The neutralizing antibody
responses against SARS-CoV-2 could give some defense against
SARS-CoV-2 infection, thus having implications for preventing
SARS-CoV-2 outbreaks. The divergence of S proteins and the
nonconserved regions of the S proteins might contribute to the
antigenicity. The highly frequent mutations identified in the S
protein may reduce the durability of the SARS-CoV-2
vaccine&#x02019;s immunity or undermine the current development
of vaccines. The existing mutations must be considered when
designing a new vaccine. Additionally, a cocktail of multiple
vaccines has a better chance of preventing COVID-19
infections.</p></sec><sec id="sec2.2.4"><label>2.2.4</label><title>Drug Discovery</title><p>Unfortunately, there is no specific effective drug for SARS-CoV-2
at this point. Potential drugs include small-molecular drugs and
antibody drugs. Much of the effort in small-molecular drug
discovery focuses on SARS-CoV-2 nonstructural proteins. Among
the major nonstructural proteins of SARS-CoV-2, the main
protease of 306 amino acids has 78 mutations with 0.255
mutations per residue and the mutation <italic>h</italic>-index
of 16, RNA polymerase of 932 amino acids has 228 mutations with
0.245 mutations per residue and the mutation
<italic>h</italic>-index of 21, and papain-like protease of 945
amino acids has 105 mutations with 0.333 mutations per residue
and the mutation <italic>h</italic>-index of 10. In fact, the
main protease is the most popular drug target because there are
no similar known genes in the human genome, which implies that
SARS-CoV-2 main protease inhibitors will likely be less
toxic.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The present study suggests
that the main protease is the second most conservative protein.
Therefore, it remains the most attractive target for drug
discovery.</p><p>Therapeutic antibodies got started from cancer treatments and now
applies to infectious diseases by targeting pathogens.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Antibody drugs are highly specificity and
versatile in the treatment of infectious diseases. Their working
principle involves the host immune system. The time used to
develop antibody therapeutics are usually considerably shorter
than that used to develop a vaccine. Many SARS-CoV-2 antibody
drugs are isolated from patient blood and target the S proteins.
Although there many binding sites on the S protein that
antibodies can target, the ones that are most effective in
neutralizing SARS-CoV-2 block the receptor-binding domain (RBD)
of the host cell angiotensin-converting enzyme 2 (ACE2)
receptor. The RBD is a dongle-shape protein at the end of the
virus&#x02019;s spikes. As mentioned above, there are many
mutations on the S proteins. The RBD is also prone to mutations.
Some mutations that break hydrogen bonds and/or salt bridges in
antibody&#x02013;antigen interactions will have a large impact.
However, silent mutations, such as those that replace
hydrophobic residues with other hydrophobic residues, will
typically have little effect. To avoid the failure of one
specific antibody, the cocktail treatments that include several
different antibodies might be required to treat SARS-CoV-2 that
undergoes antigenic mutations.</p></sec><sec id="sec2.2.5"><label>2.2.5</label><title>Protein-Specific Discussion</title><sec id="sec2.2.5.1"><label>2.2.5.1</label><title>Spike Glycoprotein</title><p>The SARS-CoV-2 spike glycoprotein, or S protein, comprised of
two subunits, S1 and S2, of very different
properties;<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> see <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>. Among
them, the S1 subunit, as shown in <xref rid="fig5" ref-type="fig">Figure
<xref rid="fig5" ref-type="fig">5</xref></xref>, contains the
receptor-binding domain (RBD) responsible for binding to
the host cell receptor angiotensin-converting enzyme 2
(ACE2). The RBD is also the common binding domain for
antibodies. The S2 subunit offers the structural support
of the S protein and mediates fusion between the viral and
host cell membranes. After the fusion, the virus releases
the viral genome into the host cell.</p><p>The S1 RBD protein plays key parts in the induction of
neutralizing-antibody and T-cell responses, as well as
protective immunity. However, S2 and extracellular domain
(ECD) of spike protein and their combination are commonly
used in recombinant proteins in SARS-CoV-2 antibody
development.</p><p>As shown in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>,
the S protein is the most heterogeneous structural protein
with a significant number of mutations as shown in <xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig">5</xref></xref> and
<xref rid="fig6" ref-type="fig">6</xref> and <xref rid="tbl6" ref-type="other">Table <xref rid="tbl6" ref-type="other">6</xref></xref>. The divergence of the spike
protein, the nonconserved regions of the spike protein
might contribute to the antigenicity difference in
SARS-CoV-2 isolates. We found that most of the high
frequent mutations of the S protein are located in the S1
subunit. <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>
indicates that near half of the amino acid residues have
had mutations since January 5, 2020. One of the important
mutations at S1 is 23010T&#x0003e;C (V483A) within the RBD for
ACE2 binding, and the total frequency of 23010T&#x0003e;C
(V483A) is 23. The structural study revealed that the
amino acids 442&#x02013;487 in the S1 subunit may impact
viral binding to human ACE2.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup>
The mutations identified in this study imply the change in
ACE2 binding affinity and the transmissibility of
SARS-CoV-2 as well as negative impacts in preventive
vaccine and diagnostic test development.</p><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Spike Surface Glycoprotein of
SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">23403A&#x0003e;G</td><td style="border:none;" align="left">D614G</td><td style="border:none;" align="char" char=".">10969</td><td style="border:none;" align="char" char=".">2333</td><td style="border:none;" align="char" char=".">2609</td><td style="border:none;" align="char" char=".">70</td><td style="border:none;" align="char" char=".">2965</td><td style="border:none;" align="char" char=".">2991</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">23731C&#x0003e;T</td><td style="border:none;" align="left">T723T</td><td style="border:none;" align="char" char=".">228</td><td style="border:none;" align="char" char=".">24</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">203</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">23929C&#x0003e;T</td><td style="border:none;" align="left">Y789Y</td><td style="border:none;" align="char" char=".">228</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">225</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">24368G&#x0003e;T</td><td style="border:none;" align="left">D936Y</td><td style="border:none;" align="char" char=".">110</td><td style="border:none;" align="char" char=".">37</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">70</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">21575C&#x0003e;T</td><td style="border:none;" align="left">L5F</td><td style="border:none;" align="char" char=".">98</td><td style="border:none;" align="char" char=".">22</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">10</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">24862A&#x0003e;G</td><td style="border:none;" align="left">T1100T</td><td style="border:none;" align="char" char=".">90</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">58</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">18</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">24390G&#x0003e;C</td><td style="border:none;" align="left">S943T</td><td style="border:none;" align="char" char=".">56</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">24389A&#x0003e;C</td><td style="border:none;" align="left">S943R</td><td style="border:none;" align="char" char=".">56</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">24933G&#x0003e;T</td><td style="border:none;" align="left">G1124V</td><td style="border:none;" align="char" char=".">47</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">21</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">3</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">23707C&#x0003e;T</td><td style="border:none;" align="left">P715P</td><td style="border:none;" align="char" char=".">44</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">39</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap></sec><sec id="sec2.2.5.2"><label>2.2.5.2</label><title>Main Protease</title><p>SARS-CoV-2 main protease, or 3CL protease, is essential for
cleaving the polyproteins that are translated from the
viral RNA.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> It operates at multiple
cleavage sites on the large polyprotein through the
proteolytic processing of replicase polyproteins and plays
a pivotal role in viral gene expression and replication.
SARS-CoV-2 main protease is one of the most attractive
targets for anti-CoV drug design because its inhibition
would block viral replication and it is unlikely to be
toxic due to no known similar human proteases. Another
reason for the focused drug discovery efforts in
developing SARS-CoV-2 main protease inhibitors is that
this protein is relatively conservative as shown in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>.</p><p><xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref> illustrates
the main protease mutation patterns. <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref> further highlights
the inhibitor binding domain (BD). Indeed, the main
protease is relatively conservative compared to the spike
protein. <xref rid="tbl7" ref-type="other">Table <xref rid="tbl7" ref-type="other">7</xref></xref>
lists top 10 mutations and their frequency in our data
set. It is interesting to see that many mutations, such as
D176D, R298R, N151N, are degenerate ones. One possible
explanation is that nondegenerates may be nonsilent and
likely cause unsurvivable disruption to the virus. Note
that mutation G15S mostly occurs in cluster IV. Mutation
R298R is restricted to cluster IV. Some other mutations,
such as D248E, A266V, N151N, and T45I are specific to
certain clusters. Nonetheless, some mutations at the BD
shown in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>
are worth noting. They can undermine the ongoing drug
discovery effort.</p><table-wrap id="tbl7" position="float"><label>Table 7</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Main Protease of SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">10097G&#x0003e;A</td><td style="border:none;" align="left">G15S</td><td style="border:none;" align="char" char=".">224</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">200</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">10323A&#x0003e;G</td><td style="border:none;" align="left">K90R</td><td style="border:none;" align="char" char=".">95</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">71</td><td style="border:none;" align="char" char=".">13</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">10798C&#x0003e;A</td><td style="border:none;" align="left">D248E</td><td style="border:none;" align="char" char=".">88</td><td style="border:none;" align="char" char=".">44</td><td style="border:none;" align="char" char=".">44</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">10851C&#x0003e;T</td><td style="border:none;" align="left">A266V</td><td style="border:none;" align="char" char=".">86</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">61</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">10582C&#x0003e;T</td><td style="border:none;" align="left">D176D</td><td style="border:none;" align="char" char=".">53</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">31</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">10319C&#x0003e;T</td><td style="border:none;" align="left">L89F</td><td style="border:none;" align="char" char=".">50</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">10948A&#x0003e;G</td><td style="border:none;" align="left">R298R</td><td style="border:none;" align="char" char=".">33</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">33</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">10507C&#x0003e;T</td><td style="border:none;" align="left">N151N</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">10265G&#x0003e;A</td><td style="border:none;" align="left">G71S</td><td style="border:none;" align="char" char=".">31</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">10188C&#x0003e;T</td><td style="border:none;" align="left">T45I</td><td style="border:none;" align="char" char=".">27</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Illustration of SARS-CoV-2 main protease
mutations using 6LU7 as a template.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0007" id="gr7" position="float"/></fig><fig id="fig8" position="float"><label>Figure 8</label><caption><p>Illustration of SARS-CoV-2 main protease binding
domain (BD) mutations of 6LU7.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0008" id="gr8" position="float"/></fig></sec><sec id="sec2.2.5.3"><label>2.2.5.3</label><title>Papain-like Protease</title><p>SARS-CoV-2 papain-like protease (PLPro) is a cysteine
cleavage protein located within the nonstructural protein
3 (NSP3) section of the viral genome.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup>
Like the main protease, PLPro activity is required to
cleave the viral polyprotein into functional, mature
subunits and, thereby, contributes to the biogenesis of
the virus replication. Additionally, PLPro possesses a
deubiquitinating activity. The SARS PLPro is also a major
therapeutic and diagnostic target.</p><p>As shown in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>,
the SARS PLPro is prone to mutations. <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref> shows that
mutations are all over the places in PLPro. <xref rid="tbl8" ref-type="other">Table <xref rid="tbl8" ref-type="other">8</xref></xref> lists the
top 10 mutations in PLPro. Three of these mutations are
degenerate ones. Note that only two of the top mutations
occurred in cluster II. In contrast, cluster I has many
different mutations.</p><table-wrap id="tbl8" position="float"><label>Table 8</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Papain-Like Protease of SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">5142C&#x0003e;T</td><td style="border:none;" align="left">T808I</td><td style="border:none;" align="char" char=".">41</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">41</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">5730C&#x0003e;T</td><td style="border:none;" align="left">T1004I</td><td style="border:none;" align="char" char=".">22</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">4</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">5784C&#x0003e;T</td><td style="border:none;" align="left">T1022I</td><td style="border:none;" align="char" char=".">19</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">17</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">5062G&#x0003e;T</td><td style="border:none;" align="left">L781F</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">5467C&#x0003e;T</td><td style="border:none;" align="left">Y916Y</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">5183C&#x0003e;T</td><td style="border:none;" align="left">P822S</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">5230G&#x0003e;T</td><td style="border:none;" align="left">K837N</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">5572G&#x0003e;T</td><td style="border:none;" align="left">M951I</td><td style="border:none;" align="char" char=".">11</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">5812C&#x0003e;T</td><td style="border:none;" align="left">D1031D</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">5284C&#x0003e;T</td><td style="border:none;" align="left">N855N</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Illustration of SARS-CoV-2 papain-like protease
mutations using 6W9C as a template.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0009" id="gr9" position="float"/></fig></sec><sec id="sec2.2.5.4"><label>2.2.5.4</label><title>RNA Polymerase</title><p>SARS RNA-dependent RNA polymerase (RdRP) is an enzyme that
catalyzes the synthesis of the SARS RNA strand
complementarily to the SARS-CoV-2 RNA template and is thus
essential to the replication of SARS-CoV-2 RNA.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> As one of the nonstructural proteins,
RdRPs are located in the early part of ORF1b section. Like
most other RNA viruses, SARS-CoV-2 RdRPs are considered to
be highly conserved to maintain viral functions and thus
targeted in antiviral drug development as well as
diagnostic tests. On the other hand, the SARS-CoV-2 RNA
polymerase lacks proofreading capability and thus its
mutations are deemed to happen as shown in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>.</p><p><xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>
illustrates the SARS-CoV-2 RdRP mutations since January 5,
2020. Surprisingly, there are many mutations in SARS-CoV-2
RdRP. <xref rid="tbl9" ref-type="other">Table <xref rid="tbl9" ref-type="other">9</xref></xref>
describes the top 10 mutations. As in other cases, five of
these mutations are degenerate ones.</p><table-wrap id="tbl9" position="float"><label>Table 9</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the RNA Dependent Polymerase of SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">14408C&#x0003e;T</td><td style="border:none;" align="left">P323L</td><td style="border:none;" align="char" char=".">10925</td><td style="border:none;" align="char" char=".">2309</td><td style="border:none;" align="char" char=".">2602</td><td style="border:none;" align="char" char=".">68</td><td style="border:none;" align="char" char=".">2955</td><td style="border:none;" align="char" char=".">2991</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">14805C&#x0003e;T</td><td style="border:none;" align="left">Y455Y</td><td style="border:none;" align="char" char=".">1242</td><td style="border:none;" align="char" char=".">9</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1202</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">15324C&#x0003e;T</td><td style="border:none;" align="left">N628N</td><td style="border:none;" align="char" char=".">405</td><td style="border:none;" align="char" char=".">128</td><td style="border:none;" align="char" char=".">253</td><td style="border:none;" align="char" char=".">18</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">13730C&#x0003e;T</td><td style="border:none;" align="left">A97V</td><td style="border:none;" align="char" char=".">263</td><td style="border:none;" align="char" char=".">11</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">232</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">13536C&#x0003e;T</td><td style="border:none;" align="left">Y32Y</td><td style="border:none;" align="char" char=".">121</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">92</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">13862C&#x0003e;T</td><td style="border:none;" align="left">T141I</td><td style="border:none;" align="char" char=".">118</td><td style="border:none;" align="char" char=".">61</td><td style="border:none;" align="char" char=".">53</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">14786C&#x0003e;T</td><td style="border:none;" align="left">A449V</td><td style="border:none;" align="char" char=".">98</td><td style="border:none;" align="char" char=".">53</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">22</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">15540C&#x0003e;T</td><td style="border:none;" align="left">V700V</td><td style="border:none;" align="char" char=".">39</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">37</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">13627G&#x0003e;T</td><td style="border:none;" align="left">D63Y</td><td style="border:none;" align="char" char=".">36</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">35</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">14877C&#x0003e;T</td><td style="border:none;" align="left">Y479Y</td><td style="border:none;" align="char" char=".">34</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">29</td></tr></tbody></table></table-wrap><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Illustration of SARS-CoV-2 RNA-polymerase
mutations using 6M71 as a template.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0010" id="gr10" position="float"/></fig></sec><sec id="sec2.2.5.5"><label>2.2.5.5</label><title>Endoribo-nuclease</title><p>Endoribo-nuclease (NendoU) protein is a nidoviral
RNAuridylate-specific enzyme that cleaves RNA.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> It contains a C-terminal catalytic
domain belonging to the NendoU family RNA processing. The
NendoU protein is presented among coronaviruses,
arteriviruses, and toroviruses. The many aspects of the
detailed function and activity of SARS-CoV-2 NendoU
protein are yet to be revealed.</p><p><xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig">11</xref></xref> depicts
SARS-CoV-2 NendoU protein mutations. As in most other
SARS-CoV-2 proteins, mutations have occurred over
different parts. <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref> shows that NendoU is relatively
conservative. <xref rid="tbl10" ref-type="other">Table <xref rid="tbl10" ref-type="other">10</xref></xref> lists the top 10 high-frequency mutations
of the SARS-CoV-2 NendoU protein that occurred in the past
few months. Four of these mutations are degenerate ones.
The frequencies of these mutations range from 153 to 15.
Note that Cluster VI only has one of these mutations.</p><table-wrap id="tbl10" position="float"><label>Table 10</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Endoribo-nuclease of SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">19839T&#x0003e;C</td><td style="border:none;" align="left">N73N</td><td style="border:none;" align="char" char=".">153</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">146</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">19684G&#x0003e;T</td><td style="border:none;" align="left">V22L</td><td style="border:none;" align="char" char=".">63</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">57</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">20578G&#x0003e;T</td><td style="border:none;" align="left">V320L</td><td style="border:none;" align="char" char=".">59</td><td style="border:none;" align="char" char=".">42</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">20134G&#x0003e;T</td><td style="border:none;" align="left">V172L</td><td style="border:none;" align="char" char=".">39</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">20148C&#x0003e;T</td><td style="border:none;" align="left">F176F</td><td style="border:none;" align="char" char=".">31</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">19999G&#x0003e;T</td><td style="border:none;" align="left">V127F</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">20316C&#x0003e;T</td><td style="border:none;" align="left">F232F</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">20270C&#x0003e;T</td><td style="border:none;" align="left">A217V</td><td style="border:none;" align="char" char=".">22</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">19</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">20275G&#x0003e;A</td><td style="border:none;" align="left">D219N</td><td style="border:none;" align="char" char=".">20</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">20031C&#x0003e;A</td><td style="border:none;" align="left">A137A</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">15</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap><fig id="fig11" position="float"><label>Figure 11</label><caption><p>Illustration of SARS-CoV-2 Endoribo-nuclease
protein mutations using 6VWW
as a template.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0011" id="gr11" position="float"/></fig></sec><sec id="sec2.2.5.6"><label>2.2.5.6</label><title>Envelope Protein</title><p>The SARS-CoV-2 envelope (E) protein is one of
SARS-CoV&#x02019;s four structural proteins. As a
transmembrane protein, it involves in ion channel activity
and thus facilitates viral assembly, budding, envelope
formation, pathogenesis, and release of the virus.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The E protein may not be essential for
viral replication, but it is for pathogenesis.</p><p><xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig">12</xref></xref>
illustrates E protein as a very small pentamer with a few
mutations. <xref rid="tbl11" ref-type="other">Table <xref rid="tbl11" ref-type="other">11</xref></xref> shows its top 10 mutations. Note that the
first four mutations are degenerate ones. All other
mutations have relatively low frequencies. As shown in
<xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>,
the SARS-CoV-2 E protein is very conservative.</p><table-wrap id="tbl11" position="float"><label>Table 11</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Envelope (E) Protein of SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">26340C&#x0003e;T</td><td style="border:none;" align="left">A32A</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">26256C&#x0003e;T</td><td style="border:none;" align="left">F4F</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">26319A&#x0003e;T</td><td style="border:none;" align="left">V25V</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">26319A&#x0003e;G</td><td style="border:none;" align="left">V25V</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">26270C&#x0003e;T</td><td style="border:none;" align="left">T9I</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">26416G&#x0003e;T</td><td style="border:none;" align="left">V58F</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">26326C&#x0003e;T</td><td style="border:none;" align="left">L28L</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">26314G&#x0003e;A</td><td style="border:none;" align="left">V24M</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">26262G&#x0003e;A</td><td style="border:none;" align="left">S6S</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">26370C&#x0003e;T</td><td style="border:none;" align="left">Y42Y</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap><fig id="fig12" position="float"><label>Figure 12</label><caption><p>Illustration of SARS-CoV-2 envelope protein
mutations using 5X29 as a template.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0012" id="gr12" position="float"/></fig></sec><sec id="sec2.2.5.7"><label>2.2.5.7</label><title>Nucleocapsid Protein</title><p>SARS-CoV-2 nucleocapsid (N) protein<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> is
another structural protein. Its primary function is to
encapsidate the viral genome. To do so, it is heavily
phosphorylated (or charged) and, thereby, can bind with
RNA. Additionally, SARS-CoV-2 N protein confirms the viral
genome to replicase-transcriptase complex (RTC) and plays
a crucial role in viral genome encapsulation. Therefore,
it may function completely differently at different stages
of the viral life cycle. SARS-CoV-2 N protein is
considered to be one of the most conservative SARS-CoV-2
proteins in the literature and is a popular target for
diagnosis of vaccine development.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> The
present works shown in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref> indicate that the SARS-CoV-2 N
protein is the worst target of any drug, vaccine, and
diagnostic development. <xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig">13</xref></xref> is the illustration of
SARS-CoV-2 nucleocapsid phosphoprotein mutations using
6VYO as a template.</p><fig id="fig13" position="float"><label>Figure 13</label><caption><p>Illustration of SARS-CoV-2 nucleocapsid
phosphoprotein mutations using 6VYO
as a template.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_0013" id="gr13" position="float"/></fig><p><xref rid="tbl12" ref-type="other">Table <xref rid="tbl12" ref-type="other">12</xref></xref> presents
the top 10 mutations of the SARS-CoV-2 N protein since
January 5, 2020. Note that only 2 out of the top 10
mutations are degenerate ones, which is a significantly
lower ratio than that of other proteins. The frequency of
10th mutation is 78, which suggests there are many
mutations associated with these mediate-sized proteins.
Most top mutations occurred to clusters I, III, and IV.
Clusters V and VI have almost none of the top 10
mutations.</p><table-wrap id="tbl12" position="float"><label>Table 12</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Nucleocapsid Phosphoprotein of
SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">28881G&#x0003e;A</td><td style="border:none;" align="left">R203K</td><td style="border:none;" align="char" char=".">3083</td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">2963</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">28882G&#x0003e;A</td><td style="border:none;" align="left">R203K</td><td style="border:none;" align="char" char=".">3076</td><td style="border:none;" align="char" char=".">96</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">2966</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">28883G&#x0003e;C</td><td style="border:none;" align="left">G204R</td><td style="border:none;" align="char" char=".">3077</td><td style="border:none;" align="char" char=".">96</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">2966</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">28311C&#x0003e;T</td><td style="border:none;" align="left">P13L</td><td style="border:none;" align="char" char=".">323</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">317</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">28657C&#x0003e;T</td><td style="border:none;" align="left">D128D</td><td style="border:none;" align="char" char=".">191</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">183</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">28688T&#x0003e;C</td><td style="border:none;" align="left">L139L</td><td style="border:none;" align="char" char=".">163</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">161</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">28836C&#x0003e;T</td><td style="border:none;" align="left">S188L</td><td style="border:none;" align="char" char=".">120</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">53</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">28878G&#x0003e;A</td><td style="border:none;" align="left">S202N</td><td style="border:none;" align="char" char=".">91</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">91</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">28580G&#x0003e;T</td><td style="border:none;" align="left">D103Y</td><td style="border:none;" align="char" char=".">79</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">74</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">29148T&#x0003e;C</td><td style="border:none;" align="left">I292T</td><td style="border:none;" align="char" char=".">78</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">73</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap></sec><sec id="sec2.2.5.8"><label>2.2.5.8</label><title>Membrane Protein</title><p>SARS-CoV-2 membrane (M) protein is another structural protein
and plays a central role in viral assembly and viral
particle formation. It exists as a dimer in the virion and
has certain geometric shapes to enable certain membrane
curvature and binding to nucleocapsid proteins. Similar to
other SARS-CoV proteins, M protein is also a popular
target for viral diagnosis and vaccines.</p><p><xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref> gives
SARS-CoV-2 M protein the middle ranking for its
conservation. <xref rid="tbl13" ref-type="other">Table <xref rid="tbl13" ref-type="other">13</xref></xref> details the top 10 mutations in SARS-CoV-2
M protein that occurred in the past few months. Eight of
these mutations are degenerate. Clusters I and V have
relatively a few of these mutations.</p><table-wrap id="tbl13" position="float"><label>Table 13</label><caption><title>Top 10 High Frequency Single SNP Genotypes in
the Membrane Glycoprotein of SARS-CoV-2</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">rank</th><th style="border:none;" align="center">SNP</th><th style="border:none;" align="center">protein mutation</th><th style="border:none;" align="center" char=".">total frequency</th><th style="border:none;" align="center" char=".">cluster I</th><th style="border:none;" align="center" char=".">cluster II</th><th style="border:none;" align="center" char=".">cluster III</th><th style="border:none;" align="center" char=".">cluster IV</th><th style="border:none;" align="center" char=".">cluster V</th><th style="border:none;" align="center" char=".">cluster VI</th></tr></thead><tbody><tr><td style="border:none;" align="left">top1</td><td style="border:none;" align="left">27046C&#x0003e;T</td><td style="border:none;" align="left">T175M</td><td style="border:none;" align="char" char=".">306</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">289</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top2</td><td style="border:none;" align="left">26530A&#x0003e;G</td><td style="border:none;" align="left">D3G</td><td style="border:none;" align="char" char=".">153</td><td style="border:none;" align="char" char=".">41</td><td style="border:none;" align="char" char=".">110</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top3</td><td style="border:none;" align="left">26729T&#x0003e;C</td><td style="border:none;" align="left">A69A</td><td style="border:none;" align="char" char=".">119</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">119</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top4</td><td style="border:none;" align="left">26951G&#x0003e;A</td><td style="border:none;" align="left">V143V</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">21</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">39</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top5</td><td style="border:none;" align="left">26750C&#x0003e;T</td><td style="border:none;" align="left">I76I</td><td style="border:none;" align="char" char=".">49</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">46</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td></tr><tr><td style="border:none;" align="left">top6</td><td style="border:none;" align="left">26681C&#x0003e;T</td><td style="border:none;" align="left">F53F</td><td style="border:none;" align="char" char=".">26</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top7</td><td style="border:none;" align="left">26864A&#x0003e;G</td><td style="border:none;" align="left">P114P</td><td style="border:none;" align="char" char=".">21</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top8</td><td style="border:none;" align="left">26936C&#x0003e;T</td><td style="border:none;" align="left">L138L</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">13</td></tr><tr><td style="border:none;" align="left">top9</td><td style="border:none;" align="left">26873C&#x0003e;T</td><td style="border:none;" align="left">N117N</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0</td></tr><tr><td style="border:none;" align="left">top10</td><td style="border:none;" align="left">26625C&#x0003e;T</td><td style="border:none;" align="left">L35L</td><td style="border:none;" align="char" char=".">17</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">0</td></tr></tbody></table></table-wrap></sec></sec></sec></sec><sec id="sec3"><label>3</label><title>Material and Methods</title><sec id="sec3.1"><label>3.1</label><title>Data Collection and Preprocessing</title><p>On January 5, 2020, the complete genome sequence of SARS-CoV-2 was first
released on GenBank (access number: NC_045512.2) by Zhang&#x02019;s
group at Fudan University.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Since then, there has
been a rapid accumulation of SARS-CoV-2 genome sequences. In this
work, 15&#x0202f;140 complete genome sequences with high coverage of
SARS-CoV-2 strains from the infected individuals in the world have
been downloaded from the GISAID database<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gisaid.org/">https://www.gisaid.org/</uri>) as
of June 1, 2020. All the records in GISAID without the exact
submission date were not taken into considerations. To rearrange the
15&#x0202f;140 complete genome sequences according to the reference
SARS-CoV-2 genome, multiple sequence alignment (MSA) was carried out
by using Clustal Omega<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> with default
parameters.</p></sec><sec id="sec3.2"><label>3.2</label><title>SNP Genotyping</title><p>SNP genotyping measures the genetic variations between different members
of a species. Establishing the SNP genotyping method for the
investigation of the genotype changes during the transmission and
evolution of SARS-CoV-2 is of great importance. By analyzing the
rearranged genome sequences, SNP profiles which record all of the SNP
positions in teams of the nucleotide changes and its corresponding
positions can be constructed. The SNP profiles of a given genome of a
COVID-19 patient capture all the differences from a complete reference
genome sequence and can be considered as the genotype of the
individual SARS-CoV-2.</p></sec><sec id="sec3.3"><label>3.3</label><title>Distance of SNP Variants</title><p>The Jaccard distance measures dissimilarity between sample sets. The
Jaccard distance of SNP variants is widely employed in the
phylogenetic analysis of human or bacterial genomes.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> In this work, we utilize the Jaccard distance to
compare the difference between the SNP variant profiles of SARS-CoV-2
genomes.</p><p>The Jaccard similarity coefficient, also known as the Jaccard index, is
defined as the intersection size divided by the union of two sets
<italic>A</italic>, <italic>B</italic>:<sup><xref ref-type="bibr" rid="ref12">12</xref></sup><disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m001" position="anchor"/><label>1</label></disp-formula>The Jaccard distance of two sets
<italic>A</italic>, <italic>B</italic> is scored as the
difference between one and the Jaccard similarity coefficient and is a
metric on the collection of all finite
sets:<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m002" position="anchor"/><label>2</label></disp-formula>Therefore, the genetic distance of
two genomes corresponds to the Jaccard distance of their SNP variants.
If <italic>A</italic> &#x02229; <italic>B</italic> &#x02260; &#x02300;,
<italic>A</italic> &#x02282; <italic>B</italic>, and
<italic>B</italic> &#x02282; <italic>A</italic>, then we say
these two SNP variants are relatives. If <italic>A</italic> &#x02282;
<italic>B</italic>, then <italic>A</italic> is the ancestor of
<italic>B</italic> and <italic>B</italic> is the descendant of
<italic>A</italic>.</p><p>In principle, the Jaccard distance measure of SNP variants takes account
of the ordering of SNP positions, i.e., transmission trajectory, when
an appropriate reference sample is selected. However, one may fail to
identify the infection pathways from the mutual Jaccard distances of
multiple samples. In this case, the dates of the sample collections
offer useful information. Additionally, clustering techniques, such as
<italic>k</italic>-means described below, enable us to
characterize the spread of COVID-19 onto the communities.</p></sec><sec id="sec3.4"><label>3.4</label><title><italic>K</italic>-Means Clustering</title><p><italic>K</italic>-means clustering is one of the fundamental
unsupervised algorithms in machine learning which aims at partitioning
a given data set <italic>X</italic> = {<italic>x</italic><sub>1</sub>,
<italic>x</italic><sub>2</sub>, ...,
<italic>x</italic><sub><italic>n</italic></sub>, ...,
<italic>x</italic><sub><italic>N</italic></sub>},
<italic>x</italic><sub><italic>n</italic></sub> &#x02208;
<inline-formula id="d31e3788"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m003.gif"/></inline-formula><sup><italic>d</italic></sup> into
<italic>k</italic> clusters {<italic>C</italic><sub>1</sub>,
<italic>C</italic><sub>2</sub>, ...,
<italic>C</italic><sub><italic>k</italic></sub>},
<italic>k</italic> &#x02264; <italic>N</italic> such that the
specific clustering criteria are optimized. More specifically, the
standard <italic>K</italic>-means clustering algorithm starts to pick
<italic>k</italic> points as cluster centers randomly and then
allocates each data to its nearest cluster. The cluster centers will
be updated iteratively by minimizing the within-cluster sum of squares
(WCSS) which is defined
by<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m004" position="anchor"/><label>3</label></disp-formula>where
&#x003bc;<sub><italic>k</italic></sub> is the mean of points
located in the <italic>k</italic>th cluster
<italic>C</italic><sub><italic>k</italic></sub> and
<italic>n</italic><sub><italic>k</italic></sub> is the number of
points in <italic>C</italic><sub><italic>k</italic></sub>. Here,
&#x02225;&#x02022;&#x02225;<sub>2</sub> denotes the
<italic>L</italic><sub>2</sub> distance.</p><p>The algorithm above only provides a way to obtain the optimal partition
for a fixed number of clusters. However, we are interested in finding
the best number of clusters for the SNP variants. Therefore, the Elbow
method is applied. By varying the number of clusters
<italic>k</italic>, a set of WCSS can be calculated in the
<italic>K</italic>-means clustering process, and then the plot
of WCSS according to the number of clusters <italic>k</italic> can be
carried out. The location of the elbow in this plot will be considered
as the optimal number of clusters. To be noticed, the WCSS measures
the variability of the points within each cluster which is influenced
by the number of points <italic>N</italic>. Therefore, as the number
of total points of <italic>N</italic> increases, the value of WCSS
becomes larger. Additionally, the performance of
<italic>k</italic>-means clustering depends on the selection of the
specific distance.</p><p>In this work, we propose to implement <italic>K</italic>-means clustering
with the Elbow method for analyzing the optimal number of the subtypes
of SARS-CoV-2 SNP variants. The Jaccard distance-based and
location-based representations are considered as the input features
for the <italic>K</italic>-means clustering method.</p><sec id="sec3.4.1"><label>3.4.1</label><title>Jaccard Distance-Based Representation</title><p>Suppose we have a total of <italic>N</italic> SNP variants
concerning a reference genome in a SARS-CoV-2 sample. The
location of the mutation sites for each SNP variant will be
saved in the set
<italic>S</italic><sub><italic>i</italic></sub>,
<italic>i</italic> = 1, 2, ..., <italic>N</italic>. The
Jaccard distance between two different sets (or samples)
<italic>S</italic><sub><italic>i</italic></sub>,
<italic>S</italic><sub><italic>j</italic></sub> is denoted
as
<italic>d</italic><sub><italic>J</italic></sub>(<italic>S</italic><sub><italic>i</italic></sub>,
<italic>S</italic><sub><italic>j</italic></sub>).
Therefore, the <italic>N</italic> &#x000d7; <italic>N</italic>
Jaccard distance-based representation will
be<disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m005" position="anchor"/><label>4</label></disp-formula></p></sec><sec id="sec3.5"><label>3.4.2</label><title>Location-Based Representation</title><p>Suppose we have <italic>N</italic> SNP variants with respect to a
reference genome in a SARS-CoV-2 sample. Among them,
<italic>M</italic> different mutation sites can be
counted. For the <italic>i</italic>th SNP variant,
<italic>V</italic><sub><italic>i</italic></sub> =
[<italic>v</italic><sub><italic>i</italic></sub><sup arrange="stack">1</sup>,
<italic>v</italic><sub><italic>i</italic></sub><sup arrange="stack">2</sup>,
..., <italic>v</italic><sub><italic>i</italic></sub><sup arrange="stack"><italic>M</italic></sup>], <italic>i</italic> = 1,
2, ..., <italic>N</italic> is a 1 &#x000d7; <italic>M</italic>
vector which satisfies the
following:<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m006" position="anchor"/><label>5</label></disp-formula>Therefore, an
<italic>N</italic> &#x000d7; <italic>M</italic>
location-based representation will
be<disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_m007" position="anchor"/><label>6</label></disp-formula></p></sec><sec id="sec3.5.1"><label>3.4.3</label><title>Principal Component Analysis (PCA)</title><p>Hundreds of complete genome sequences are deposited to GISAID every
day, which results in an ever-growing massive quantity of high
dimensional data representations for the
<italic>K</italic>-means clustering. For example, if the data
set of an organism involves 10&#x0202f;000 SNPs, the initial
representation will be a 10&#x0202f;000-dimensional vector for
each sample, which can be computationally difficult for a simple
<italic>K</italic>-means clustering algorithm. Therefore,
a dimensionality reduction method is used to preprocess the
data. The essential idea of PCA-based <italic>K</italic>-means
clustering is to invoke the PCA to obtain a reduced-dimensional
representation of each sample before performing the
<italic>K</italic>-means clustering. In practice, one can
select a few lowest dimensional principal components as the
<italic>K</italic>-means input for each sample. In ref
(<xref ref-type="bibr" rid="ref5">5</xref>), the authors
proved that the principal components are the continuous solution
of the cluster indicators in the <italic>K</italic>-means
clustering method, which provides us a rigorous mathematical
tool to embed our high-dimensional data into a low-dimensional
PCA subspace.</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Conclusion</title><p>The rapid global transmission of coronavirus disease 2019 (COVID-19) has
offered some of the most heterogeneous, diverse, and challenging mutagenic
environments to stimulate dramatic genetic evolution and response from
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This work
provides the most comprehensive genotyping of SARS-CoV-2 transmission and
evolution up to date based on 15&#x0202f;140 genome samples and reveals six
clusters of the COVID-19 genomes and associated mutations on eight different
SARS-CoV-2 proteins. We introduce mutation <italic>h</italic>-index and
mutation ratio to qualify individual protein&#x02019;s degree of
nonconservativeness. We unveil that SARS-CoV-2 envelope protein, main
protease, and endoribonuclease protein are relatively the most conservative,
whereas SARS-CoV-2 nucleocapsid protein, spike protein, and papain-like
protease are relatively the most nonconservative. We report that all of the
SARS-CoV-2 proteins have undergone intensive mutations since January 5,
2020, and some of these mutations might seriously undermine ongoing efforts
on COVID-19 diagnostic testing, vaccine development, antibody therapeutics,
and small-molecular drug discovery.</p></sec><sec sec-type="data-availability" id="sec5"><label>5</label><title>Data Availability</title><p>The nucleotide sequences of the SARS-CoV-2 genomes used in this analysis are
available, upon free registration, from the GISAID database (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gisaid.org/">https://www.gisaid.org/</uri>).
Eighteen tables are provided in the <xref rid="notes1" ref-type="notes">Supporting
Information</xref> for SNP variants of 15&#x0202f;140 SARS-CoV-2
samples across the world, SNP variants of 4587 SARS-CoV-2 samples in the US,
SNP variants in six global clusters, SNP variants in four US clusters, and
mutation records for eight SARS-CoV-2 proteins. The acknowledgments of the
SARS-COV-2 genomes are also given in the <xref rid="notes1" ref-type="notes">Supporting
Information</xref>.</p></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.0c00501?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00501</ext-link>.<list id="silist" list-type="simple"><list-item><p>Figures of
<italic>K</italic>-mean clustering for optimal
groups and detailed description of supplementary tables
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00501/suppl_file/ci0c00501_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p>Supplementary
tables (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00501/suppl_file/ci0c00501_si_002.xlsx">XLSX</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_si_001.pdf"><caption><p>ci0c00501_si_001.pdf</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00501_si_002.xlsx"><caption><p>ci0c00501_si_002.xlsx</p></caption></media></supplementary-material></sec><notes notes-type="COI-statement" id="NOTES-d7e4532-autogenerated"><p>The authors declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work was supported in part by NIH grant GM126189, NSF Grants DMS-1721024,
DMS-1761320, and IIS1900473, Michigan Economic Development Corporation,
Bristol-Myers Squibb, and Pfizer. The authors thank The IBM TJ Watson
Research Center, The COVID-19 High Performance Computing Consortium, NVIDIA,
and MSU HPCC for computational assistance.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Cao</surname><given-names>Y.</given-names></name>; <name><surname>Su</surname><given-names>B.</given-names></name>; <name><surname>Guo</surname><given-names>X.</given-names></name>; <name><surname>Sun</surname><given-names>W.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Bao</surname><given-names>L.</given-names></name>; <name><surname>Zhu</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Zheng</surname><given-names>Y.</given-names></name>; <name><surname>Geng</surname><given-names>C.</given-names></name>; <name><surname>Chai</surname><given-names>X.</given-names></name>; <name><surname>He</surname><given-names>R.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Lv</surname><given-names>Q.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Deng</surname><given-names>W.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Xie</surname><given-names>X.</given-names></name>
<article-title>Potent neutralizing antibodies against SARS-CoV-2
identified by high-throughput single-cell sequencing of
convalescent patients b cells</article-title>. <source>Cell</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.025</pub-id>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="book" id="cit2"><person-group person-group-type="allauthors"><name><surname>Chang</surname><given-names>C.</given-names></name>;
<name><surname>Michalska</surname><given-names>K.</given-names></name>;
<name><surname>Jedrzejczak</surname><given-names>R.</given-names></name>;
<name><surname>Maltseva</surname><given-names>N.</given-names></name>;
<name><surname>Endres</surname><given-names>M.</given-names></name>;
<name><surname>Godzik</surname><given-names>A.</given-names></name>;
<name><surname>Kim</surname><given-names>Y.</given-names></name>;
<name><surname>Joachimiak</surname><given-names>A.</given-names></name></person-group><article-title>Crystal structure of RNA binding domain of nucleocapsid
phosphoprotein from SARS coronavirus 2</article-title>.
<source>Wordwide PDB</source>;
<year>2020</year>;<pub-id pub-id-type="doi">10.2210/pdb6VYO/pdb</pub-id>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Corman</surname><given-names>V. M.</given-names></name>; <name><surname>Landt</surname><given-names>O.</given-names></name>; <name><surname>Kaiser</surname><given-names>M.</given-names></name>; <name><surname>Molenkamp</surname><given-names>R.</given-names></name>; <name><surname>Meijer</surname><given-names>A.</given-names></name>; <name><surname>Chu</surname><given-names>D. K.</given-names></name>; <name><surname>Bleicker</surname><given-names>T.</given-names></name>; <name><surname>Brnink</surname><given-names>S.</given-names></name>; <name><surname>Schneider</surname><given-names>J.</given-names></name>; <name><surname>Schmidt</surname><given-names>M. L.</given-names></name>; <name><surname>Mulders</surname><given-names>D. G.</given-names></name>; <name><surname>Haagmans</surname><given-names>B. L.</given-names></name>; <name><surname>van der Veer</surname><given-names>B.</given-names></name>; <name><surname>van den Brink</surname><given-names>S.</given-names></name>; <name><surname>Wijsman</surname><given-names>L.</given-names></name>; <name><surname>Goderski</surname><given-names>G.</given-names></name>; <name><surname>Romette</surname><given-names>J.-L.</given-names></name>; <name><surname>Ellis</surname><given-names>J.</given-names></name>; <name><surname>Zambon</surname><given-names>M.</given-names></name>; <name><surname>Peiris</surname><given-names>M.</given-names></name>; <name><surname>Goossens</surname><given-names>H.</given-names></name>; <name><surname>Reusken</surname><given-names>C.</given-names></name>; <name><surname>Koopmans</surname><given-names>M. P.</given-names></name>; <name><surname>Drosten</surname><given-names>C.</given-names></name>
<article-title>Detection of 2019 novel coronavirus (2019-ncov) by
real-time RT-PCR</article-title>. <source>Eurosurveillance</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id>.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>DeDiego</surname><given-names>M. L.</given-names></name>; <name><surname>Nieto-Torres</surname><given-names>J. L.</given-names></name>; <name><surname>Jim&#x000e9;nez-Guarde&#x000f1;o</surname><given-names>J. M.</given-names></name>; <name><surname>Regla-Nava</surname><given-names>J. A.</given-names></name>; <name><surname>Alvarez</surname><given-names>E.</given-names></name>; <name><surname>Oliveros</surname><given-names>J. C.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Fett</surname><given-names>C.</given-names></name>; <name><surname>Perlman</surname><given-names>S.</given-names></name>; <name><surname>Enjuanes</surname><given-names>L.</given-names></name>
<article-title>Severe acute respiratory syndrome coronavirus envelope
protein regulates cell stress response and
apoptosis</article-title>. <source>PLoS Pathog.</source>
<year>2011</year>, <volume>7</volume> (<issue>10</issue>), <fpage>e1002315</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002315</pub-id>.<pub-id pub-id-type="pmid">22028656</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="conf-proc" id="cit5"><person-group person-group-type="allauthors"><name><surname>Ding</surname><given-names>C.</given-names></name>;
<name><surname>He</surname><given-names>X.</given-names></name></person-group><article-title>K-means clustering via principal component
analysis</article-title>. In <source>Proceedings of the
twenty-first international conference on Machine
learning</source>, <year>2004</year>, p
<fpage>29</fpage>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Ferron</surname><given-names>F.</given-names></name>; <name><surname>Subissi</surname><given-names>L.</given-names></name>; <name><surname>Silveira De Morais</surname><given-names>A. T.</given-names></name>; <name><surname>Le</surname><given-names>N. T. T.</given-names></name>; <name><surname>Sevajol</surname><given-names>M.</given-names></name>; <name><surname>Gluais</surname><given-names>L.</given-names></name>; <name><surname>Decroly</surname><given-names>E.</given-names></name>; <name><surname>Vonrhein</surname><given-names>C.</given-names></name>; <name><surname>Bricogne</surname><given-names>G.</given-names></name>; <name><surname>Canard</surname><given-names>B.</given-names></name>; <name><surname>Imbert</surname><given-names>I.</given-names></name>
<article-title>Structural and molecular basis of mismatch correction
and ribavirin excision from coronavirus RNA</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2018</year>, <volume>115</volume> (<issue>2</issue>), <fpage>E162</fpage>&#x02013;<lpage>E171</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1718806115</pub-id>.<pub-id pub-id-type="pmid">29279395</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Follis</surname><given-names>K. E.</given-names></name>; <name><surname>York</surname><given-names>J.</given-names></name>; <name><surname>Nunberg</surname><given-names>J. H.</given-names></name>
<article-title>Furin cleavage of the SARS coronavirus spike
glycoprotein enhances cell&#x02013;cell fusion but does not
affect virion entry</article-title>. <source>Virology</source>
<year>2006</year>, <volume>350</volume> (<issue>2</issue>), <fpage>358</fpage>&#x02013;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2006.02.003</pub-id>.<pub-id pub-id-type="pmid">16519916</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Yan</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>F.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Cao</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>T.</given-names></name>; <name><surname>Sun</surname><given-names>Q.</given-names></name>; <name><surname>Ming</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Ge</surname><given-names>J.</given-names></name>; <name><surname>Zheng</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>C.</given-names></name>; <name><surname>Hu</surname><given-names>T.</given-names></name>; <name><surname>Hua</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Guddat</surname><given-names>L. W.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Lou</surname><given-names>Z.</given-names></name>; <name><surname>Rao</surname><given-names>Z.</given-names></name>
<article-title>Structure of the rna-dependent rna polymerase from
COVID-19 virus</article-title>. <source>Science</source>
<year>2020</year>, <volume>368</volume> (<issue>6492</issue>), <fpage>779</fpage>&#x02013;<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7498</pub-id>.<pub-id pub-id-type="pmid">32277040</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Hoffmann</surname><given-names>M.</given-names></name>; <name><surname>Kleine-Weber</surname><given-names>H.</given-names></name>; <name><surname>Schroeder</surname><given-names>S.</given-names></name>; <name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name>; <name><surname>Herrler</surname><given-names>T.</given-names></name>; <name><surname>Erichsen</surname><given-names>S.</given-names></name>; <name><surname>Schiergens</surname><given-names>T. S.</given-names></name>; <name><surname>Herrler</surname><given-names>G.</given-names></name>; <name><surname>Wu</surname><given-names>N.-H.</given-names></name>; <name><surname>Nitsche</surname><given-names>A.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>M. A.</given-names></name>; <name><surname>Drosten</surname><given-names>C.</given-names></name>; <name><surname>P&#x000fc;hlmann</surname><given-names>S.</given-names></name>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and
is blocked by a clinically proven protease
inhibitor</article-title>. <source>Cell</source>
<year>2020</year>, <volume>181</volume>, <fpage>271</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>.<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Jin</surname><given-names>Z.</given-names></name>; <name><surname>Du</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Peng</surname><given-names>C.</given-names></name>
<article-title>Structure of Mpro from SARS-CoV-2 and discovery of its
inhibitors</article-title>. <source>Nature</source>
<year>2020</year>, <volume>582</volume>, <fpage>289</fpage><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id>.<pub-id pub-id-type="pmid">32272481</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Kim</surname><given-names>Y.</given-names></name>; <name><surname>Jedrzejczak</surname><given-names>R.</given-names></name>; <name><surname>Maltseva</surname><given-names>N. I.</given-names></name>; <name><surname>Wilamowski</surname><given-names>M.</given-names></name>; <name><surname>Endres</surname><given-names>M.</given-names></name>; <name><surname>Godzik</surname><given-names>A.</given-names></name>; <name><surname>Michalska</surname><given-names>K.</given-names></name>; <name><surname>Joachimiak</surname><given-names>A.</given-names></name>
<article-title>Crystal structure of nsp15 endoribonuclease nendou from
SARS-CoV-2</article-title>. <source>Protein Sci.</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1002/pro.3873</pub-id>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Levandowsky</surname><given-names>M.</given-names></name>; <name><surname>Winter</surname><given-names>D.</given-names></name>
<article-title>Distance between sets</article-title>. <source>Nature</source>
<year>1971</year>, <volume>234</volume> (<issue>5323</issue>), <fpage>34</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/234034a0</pub-id>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>McBride</surname><given-names>R.</given-names></name>; <name><surname>Van Zyl</surname><given-names>M.</given-names></name>; <name><surname>Fielding</surname><given-names>B. C.</given-names></name>
<article-title>The coronavirus nucleocapsid is a multifunctional
protein</article-title>. <source>Viruses</source>
<year>2014</year>, <volume>6</volume> (<issue>8</issue>), <fpage>2991</fpage>&#x02013;<lpage>3018</lpage>. <pub-id pub-id-type="doi">10.3390/v6082991</pub-id>.<pub-id pub-id-type="pmid">25105276</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Moya</surname><given-names>A.</given-names></name>; <name><surname>Holmes</surname><given-names>E. C.</given-names></name>; <name><surname>Gonz&#x000e1;lez-Candelas</surname><given-names>F.</given-names></name>
<article-title>The population genetics and evolutionary epidemiology
of RNA viruses</article-title>. <source>Nat. Rev. Microbiol.</source>
<year>2004</year>, <volume>2</volume> (<issue>4</issue>), <fpage>279</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro863</pub-id>.<pub-id pub-id-type="pmid">15031727</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><article-title>The species severe acute respiratory syndrome-related
coronavirus: classifying 2019-ncov and naming it
SARS-CoV-2</article-title>. <source>Nature Microbiology</source>
<year>2020</year>, <volume>5</volume> (<issue>4</issue>), <fpage>536</fpage><pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Ojosnegros</surname><given-names>S.</given-names></name>; <name><surname>Beerenwinkel</surname><given-names>N.</given-names></name>
<article-title>Models of RNA virus evolution and their roles in
vaccine design</article-title>. <source>Immunome Res.</source>
<year>2010</year>, <volume>6</volume> (<issue>S2</issue>), <fpage>S5</fpage><pub-id pub-id-type="doi">10.1186/1745-7580-6-S2-S5</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="book" id="cit17"><person-group person-group-type="allauthors"><name><surname>Osipiuk</surname><given-names>J.</given-names></name>;
<name><surname>Jedrzejczak</surname><given-names>R.</given-names></name>;
<name><surname>Tesar</surname><given-names>C.</given-names></name>;
<name><surname>Endres</surname><given-names>M.</given-names></name>;
<name><surname>Stols</surname><given-names>L.</given-names></name>;
<name><surname>Babnigg</surname><given-names>G.</given-names></name>;
<name><surname>Kim</surname><given-names>Y.</given-names></name>;
<name><surname>Michalska</surname><given-names>K.</given-names></name>;
<name><surname>Joachimiak</surname><given-names>A.</given-names></name></person-group><article-title>The crystal structure of papain-like protease of SARS
CoV-2</article-title>. <source>Wordwide PDB</source>;
<year>2020</year>;<pub-id pub-id-type="doi">10.2210/pdb6w9c/pdb</pub-id>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Raoult</surname><given-names>D.</given-names></name>; <name><surname>Zumla</surname><given-names>A.</given-names></name>; <name><surname>Locatelli</surname><given-names>F.</given-names></name>; <name><surname>Ippolito</surname><given-names>G.</given-names></name>; <name><surname>Kroemer</surname><given-names>G.</given-names></name>
<article-title>Coronavirus infections: Epidemiological, clinical and
immunological features and hypotheses</article-title>. <source>Cell Stress</source>
<year>2020</year>, <volume>4</volume> (<issue>4</issue>), <fpage>66</fpage><pub-id pub-id-type="doi">10.15698/cst2020.04.216</pub-id>.<pub-id pub-id-type="pmid">32292881</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Ren</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Zhao</surname><given-names>Z.</given-names></name>; <name><surname>Wen</surname><given-names>J.</given-names></name>; <name><surname>Zhou</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Yin</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>N.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>
<article-title>A strategy for searching antigenic regions in the
SARS-CoV spike protein</article-title>. <source>Genomics, Proteomics Bioinf.</source>
<year>2003</year>, <volume>1</volume> (<issue>3</issue>), <fpage>207</fpage>&#x02013;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/S1672-0229(03)01026-X</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Shu</surname><given-names>Y.</given-names></name>; <name><surname>McCauley</surname><given-names>J.</given-names></name>
<source>Eurosurveillance</source>
<year>2017</year>, <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.13.30494</pub-id>.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Sievers</surname><given-names>F.</given-names></name>; <name><surname>Higgins</surname><given-names>D. G.</given-names></name>
<article-title>Clustal omega</article-title>. <source>Current Protocols in Bioinformatics</source>
<year>2014</year>, <volume>48</volume> (<issue>1</issue>), <fpage>3</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1002/0471250953.bi0313s48</pub-id>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Surya</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Torres</surname><given-names>J.</given-names></name>
<article-title>Structural model of the SARS coronavirus E channel in
LMPG micelles</article-title>. <source>Biochim. Biophys. Acta, Biomembr.</source>
<year>2018</year>, <volume>1860</volume>, <fpage>1309</fpage>&#x02013;<lpage>1317</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2018.02.017</pub-id>.<pub-id pub-id-type="pmid">29474890</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Tang</surname><given-names>X.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Song</surname><given-names>Y.</given-names></name>; <name><surname>Yao</surname><given-names>X.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Duan</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Qian</surname><given-names>Z.</given-names></name>; <name><surname>Cui</surname><given-names>J.</given-names></name>; <name><surname>Lu</surname><given-names>J.</given-names></name>
<article-title>On the origin and continuing evolution of
SARS-CoV-2</article-title>. <source>Nat. Sci. Rev.</source>
<year>2020</year>, <volume>7</volume>, <fpage>1012</fpage><pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Udugama</surname><given-names>B.</given-names></name>; <name><surname>Kadhiresan</surname><given-names>P.</given-names></name>; <name><surname>Kozlowski</surname><given-names>H. N.</given-names></name>; <name><surname>Malekjahani</surname><given-names>A.</given-names></name>; <name><surname>Osborne</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>V. Y.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Mubareka</surname><given-names>S.</given-names></name>; <name><surname>Gubbay</surname><given-names>J.</given-names></name>; <name><surname>Chan</surname><given-names>W. C.</given-names></name>
<article-title>Diagnosing COVID-19: The disease and tools for
detection</article-title>. <source>ACS Nano</source>
<year>2020</year>, <volume>14</volume>, <fpage>3822</fpage><pub-id pub-id-type="doi">10.1021/acsnano.0c02624</pub-id>.<pub-id pub-id-type="pmid">32223179</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Walls</surname><given-names>A. C.</given-names></name>; <name><surname>Park</surname><given-names>Y.-J.</given-names></name>; <name><surname>Tortorici</surname><given-names>M. A.</given-names></name>; <name><surname>Wall</surname><given-names>A.</given-names></name>; <name><surname>McGuire</surname><given-names>A. T.</given-names></name>; <name><surname>Veesler</surname><given-names>D.</given-names></name>
<article-title>Structure, function, and antigenicity of the SARS-CoV-2
spike glycoprotein</article-title>. <source>Cell</source>
<year>2020</year>, <volume>181</volume>, <fpage>281</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id>.<pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Wan</surname><given-names>Y.</given-names></name>; <name><surname>Shang</surname><given-names>J.</given-names></name>; <name><surname>Graham</surname><given-names>R.</given-names></name>; <name><surname>Baric</surname><given-names>R. S.</given-names></name>; <name><surname>Li</surname><given-names>F.</given-names></name>
<article-title>Receptor recognition by the novel coronavirus from
Wuhan: an analysis based on decade-long structural studies of
SARS coronavirus</article-title>. <source>J. Virol.</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="book" id="cit27"><person-group person-group-type="allauthors"><collab>WHO</collab></person-group>. <source>Coronavirus
disease 2019 (COVID-19) situation report 133</source>;
<year>2020</year>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Wu</surname><given-names>F.</given-names></name>; <name><surname>Zhao</surname><given-names>S.</given-names></name>; <name><surname>Yu</surname><given-names>B.</given-names></name>; <name><surname>Chen</surname><given-names>Y.-M.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Song</surname><given-names>Z.-G.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Tao</surname><given-names>Z.-W.</given-names></name>; <name><surname>Tian</surname><given-names>J.-H.</given-names></name>; <name><surname>Pei</surname><given-names>Y.-Y.</given-names></name>; <name><surname>Yuan</surname><given-names>M.-L.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.-L.</given-names></name>; <name><surname>Dai</surname><given-names>F.-H.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Q.-M.</given-names></name>; <name><surname>Zheng</surname><given-names>J.-J.</given-names></name>; <name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Holmes</surname><given-names>E. C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.-Z.</given-names></name>
<article-title>A new coronavirus associated with human respiratory
disease in China</article-title>. <source>Nature</source>
<year>2020</year>, <volume>579</volume> (<issue>7798</issue>), <fpage>265</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id>.<pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Xiao</surname><given-names>X.</given-names></name>; <name><surname>Chakraborti</surname><given-names>S.</given-names></name>; <name><surname>Dimitrov</surname><given-names>A. S.</given-names></name>; <name><surname>Gramatikoff</surname><given-names>K.</given-names></name>; <name><surname>Dimitrov</surname><given-names>D. S.</given-names></name>
<article-title>The SARS-CoV s glycoprotein: expression and functional
characterization</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<year>2003</year>, <volume>312</volume> (<issue>4</issue>), <fpage>1159</fpage>&#x02013;<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2003.11.054</pub-id>.<pub-id pub-id-type="pmid">14651994</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Yin</surname><given-names>C.</given-names></name>
<article-title>Genotyping coronavirus SARS-CoV-2: methods and
implications</article-title>. <source>Genomics</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1016/j.ygeno.2020.04.016</pub-id>.</mixed-citation></ref></ref-list></back></article>